{"disease":{"id":"activating-egfr-mutation","name":"activating egfr mutation"},"drugs":{"marketed":[{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with an activating EGFR mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05241873","title":"(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT06685718","title":"A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT06363734","title":"Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT01941654","title":"ATOM_local Ablative Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03944265","title":"Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Thomas Jefferson University","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}